These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

544 related articles for article (PubMed ID: 17416761)

  • 1. Incidence and duration of cervical human papillomavirus 6, 11, 16, and 18 infections in young women: an evaluation from multiple analytic perspectives.
    Insinga RP; Dasbach EJ; Elbasha EH; Liaw KL; Barr E
    Cancer Epidemiol Biomarkers Prev; 2007 Apr; 16(4):709-15. PubMed ID: 17416761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women.
    Insinga RP; Perez G; Wheeler CM; Koutsky LA; Garland SM; Leodolter S; Joura EA; Ferris DG; Steben M; Brown DR; Elbasha EH; Paavonen J; Haupt RM;
    Cancer Epidemiol Biomarkers Prev; 2010 Jun; 19(6):1585-94. PubMed ID: 20530494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and predictors of human papillomavirus-6, -11, -16, and -18 infection in young norwegian women.
    Kim S; Arduino JM; Roberts CC; Marsico M; Liaw KL; Skjeldestad FE
    Sex Transm Dis; 2011 Jul; 38(7):587-97. PubMed ID: 21301390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baseline demographic characteristics of subjects enrolled in international quadrivalent HPV (types 6/11/16/18) vaccine clinical trials.
    Paavonen J;
    Curr Med Res Opin; 2008 Jun; 24(6):1623-34. PubMed ID: 18435868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence, prevalence, and clearance of type-specific human papillomavirus infections: The Young Women's Health Study.
    Giuliano AR; Harris R; Sedjo RL; Baldwin S; Roe D; Papenfuss MR; Abrahamsen M; Inserra P; Olvera S; Hatch K
    J Infect Dis; 2002 Aug; 186(4):462-9. PubMed ID: 12195372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and incidence of HPV genital infection in women.
    Velicer C; Zhu X; Vuocolo S; Liaw KL; Saah A
    Sex Transm Dis; 2009 Nov; 36(11):696-703. PubMed ID: 19652630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The natural history of type-specific human papillomavirus infections in female university students.
    Richardson H; Kelsall G; Tellier P; Voyer H; Abrahamowicz M; Ferenczy A; Coutlée F; Franco EL
    Cancer Epidemiol Biomarkers Prev; 2003 Jun; 12(6):485-90. PubMed ID: 12814991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of high-risk human papillomavirus type 16/18 infection among women with normal cytology: risk factor analysis and implications for screening and prophylaxis.
    Gupta S; Sodhani P; Sharma A; Sharma JK; Halder K; Charchra KL; Sardana S; Singh V; Sehgal A; Das BC
    Cytopathology; 2009 Aug; 20(4):249-55. PubMed ID: 19018810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human papillomavirus type-distribution in the cervix of Chinese women: a meta-analysis.
    Bao YP; Li N; Smith JS; Qiao YL
    Int J STD AIDS; 2008 Feb; 19(2):106-11. PubMed ID: 18334063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human papillomavirus infections and vulvar disease development.
    Garland SM; Insinga RP; Sings HL; Haupt RM; Joura EA
    Cancer Epidemiol Biomarkers Prev; 2009 Jun; 18(6):1777-84. PubMed ID: 19505910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine.
    Garland SM; Steben M; Sings HL; James M; Lu S; Railkar R; Barr E; Haupt RM; Joura EA
    J Infect Dis; 2009 Mar; 199(6):805-14. PubMed ID: 19199546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cervical human papillomavirus incidence and persistence in a cohort of HIV-negative women in Zimbabwe.
    Fukuchi E; Sawaya GF; Chirenje M; Magure T; Tuveson J; Ma Y; Shiboski S; Da Costa M; Palefsky J; Moscicki AB; Makunike-Mutasa R; Chipato T; Smith-McCune KK
    Sex Transm Dis; 2009 May; 36(5):305-11. PubMed ID: 19295468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human papillomavirus vaccine for genotypes 6, 11, 16 and 18: new drug. Cervical cancer prevention: high hopes...
    Prescrire Int; 2007 Jun; 16(89):91-4. PubMed ID: 17582921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repeated evaluation of human papillomavirus 16 status in cervical swabs of young women with a history of normal Papanicolaou smears.
    Schneider A; Kirchhoff T; Meinhardt G; Gissmann L
    Obstet Gynecol; 1992 May; 79(5 ( Pt 1)):683-8. PubMed ID: 1314360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer.
    Franco EL; Villa LL; Sobrinho JP; Prado JM; Rousseau MC; Désy M; Rohan TE
    J Infect Dis; 1999 Nov; 180(5):1415-23. PubMed ID: 10515798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine.
    Olsson SE; Villa LL; Costa RL; Petta CA; Andrade RP; Malm C; Iversen OE; Høye J; Steinwall M; Riis-Johannessen G; Andersson-Ellstrom A; Elfgren K; von Krogh G; Lehtinen M; Paavonen J; Tamms GM; Giacoletti K; Lupinacci L; Esser MT; Vuocolo SC; Saah AJ; Barr E
    Vaccine; 2007 Jun; 25(26):4931-9. PubMed ID: 17499406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years.
    Brown DR; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Koutsky LA; Tay EH; Garcia P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Joura EA; Kurman RJ; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan J; Lupinacci LC; Giacoletti KE; Sings HL; James M; Hesley TM; Barr E
    J Infect Dis; 2009 Apr; 199(7):926-35. PubMed ID: 19236279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and type distribution of high-risk human papillomavirus infection in women undergoing voluntary cervical cancer screening in Italy.
    Agarossi A; Ferrazzi E; Parazzini F; Perno CF; Ghisoni L
    J Med Virol; 2009 Mar; 81(3):529-35. PubMed ID: 19152401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses.
    David MP; Van Herck K; Hardt K; Tibaldi F; Dubin G; Descamps D; Van Damme P
    Gynecol Oncol; 2009 Dec; 115(3 Suppl):S1-6. PubMed ID: 19217149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cervical and oral human papillomavirus types in HIV-1 positive and negative women with cervical disease in South Africa.
    Marais DJ; Passmore JA; Denny L; Sampson C; Allan BR; Williamson AL
    J Med Virol; 2008 Jun; 80(6):953-9. PubMed ID: 18428143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.